{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:28:37Z","timestamp":1793734117448,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP microbone"],"award-info":[{"award-number":["SPP microbone"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00763-8","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:01:53Z","timestamp":1713506513000},"page":"1318-1333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-9289","authenticated-orcid":false,"given":"Michael","family":"Rade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaren","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Scolnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kloetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Kubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Baber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-8750","authenticated-orcid":false,"given":"Song Yau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule","family":"Ussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe","family":"Schetschorke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Hell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-2332","authenticated-orcid":false,"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-4872","authenticated-orcid":false,"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.3390\/cancers13235996","volume":"13","author":"M Merz","year":"2021","unstructured":"Merz, M. et al. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. Cancers 13, 5996 (2021).","journal-title":"Cancers"},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"763_CR4","doi-asserted-by":"crossref","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2022).","DOI":"10.1200\/JCO.22.00842"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"key":"763_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","volume":"9","author":"N Gagelmann","year":"2022","unstructured":"Gagelmann, N. et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. Lancet Haematol. 9, e786\u2013e795 (2022).","journal-title":"Lancet Haematol."},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","volume":"5","author":"N Gazeau","year":"2021","unstructured":"Gazeau, N. et al. Effective anti-BCMA retreatment in multiple myeloma. Blood Adv. 5, 3016\u20133020 (2021).","journal-title":"Blood Adv."},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng, H. et al. Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front. Immunol. 12, 720571 (2021).","journal-title":"Front. Immunol."},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"763_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih, A. et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11, 219 (2020).","journal-title":"Nat. Commun."},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"eabj2820","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"763_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33944-z","volume":"13","author":"R Boiarsky","year":"2022","unstructured":"Boiarsky, R. et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat. Commun. 13, 7040 (2022).","journal-title":"Nat. Commun."},{"key":"763_CR14","doi-asserted-by":"crossref","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491\u2013503 (2021).","DOI":"10.1038\/s41591-021-01232-w"},{"key":"763_CR15","doi-asserted-by":"crossref","unstructured":"Dutta, A. K. et al. Single-cell profiling of tumour evolution in multiple myeloma\u2014opportunities for precision medicine. Nat. Rev. Clin. Oncol. 19, 223\u2013236 (2022).","DOI":"10.1038\/s41571-021-00593-y"},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"763_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28266-z","volume":"13","author":"M Merz","year":"2022","unstructured":"Merz, M. et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat. Commun. 13, 807 (2022).","journal-title":"Nat. Commun."},{"key":"763_CR18","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1093\/bioinformatics\/btac582","volume":"38","author":"B Phipson","year":"2022","unstructured":"Phipson, B. et al. propeller: testing for differences in cell type proportions in single cell data. Bioinformatics 38, 4720\u20134726 (2022).","journal-title":"Bioinformatics"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K., Smyth, M. J. & Martinet, L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood 136, 2731\u20132740 (2020).","journal-title":"Blood"},{"key":"763_CR23","doi-asserted-by":"crossref","unstructured":"Merz, M. et al. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 7, 718\u2013733 (2022).","DOI":"10.1182\/bloodadvances.2022007457"},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 (2020).","journal-title":"Nat. Cancer"},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.3390\/cells11223700","volume":"11","author":"AN Clements","year":"2022","unstructured":"Clements, A. N. & Warfel, N. A. Targeting PIM kinases to improve the efficacy of immunotherapy. Cells 11, 3700 (2022).","journal-title":"Cells"},{"key":"763_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.46","volume":"5","author":"NA Keane","year":"2015","unstructured":"Keane, N. A., Reidy, M., Natoni, A., Raab, M. S. & O\u2019Dwyer, M. Targeting the Pim kinases in multiple myeloma. Blood Cancer J. 5, e325 (2015).","journal-title":"Blood Cancer J."},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-18-0706","volume":"25","author":"S Chatterjee","year":"2019","unstructured":"Chatterjee, S. et al. Targeting PIM kinase with PD1 inhibition improves immunotherapeutic antitumor T-cell response. Clin. Cancer Res. 25, 1036\u20131049 (2019).","journal-title":"Clin. Cancer Res."},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","volume":"20","author":"AK Moesta","year":"2020","unstructured":"Moesta, A. K., Li, X.-Y. & Smyth, M. J. Targeting CD39 in cancer. Nat. Rev. Immunol. 20, 739\u2013755 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"763_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/01.HS9.0000844040.56318.a6","volume":"6","author":"V Vucinic","year":"2022","unstructured":"Vucinic, V. et al. S287: factors influencing autologous lymphocyte collections for chimeric antigen receptor (CAR) T-cells\u2014the role of T-cell senescence. HemaSphere 6, 188 (2022).","journal-title":"HemaSphere"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","volume":"5","author":"P-H Chen","year":"2020","unstructured":"Chen, P.-H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020).","journal-title":"JCI Insight"},{"key":"763_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490\u2013501 (2022).","journal-title":"Blood Cancer Discov."},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson, N. D. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184, 1281\u20131298 (2021).","journal-title":"Cell"},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-140243","volume":"136","author":"B Wang","year":"2020","unstructured":"Wang, B. et al. Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease\u2014a single institution observation in China. Blood 136, 6 (2020).","journal-title":"Blood"},{"key":"763_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2022.281339","volume":"108","author":"E Garc\u00eda-Guerrero","year":"2023","unstructured":"Garc\u00eda-Guerrero, E. et al. All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica 108, 568\u2013580 (2023).","journal-title":"Haematologica"},{"key":"763_CR36","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41375-019-0634-2","volume":"34","author":"M Merz","year":"2020","unstructured":"Merz, M. et al. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. Leukemia 34, 1192\u20131196 (2020).","journal-title":"Leukemia"},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","volume":"2","author":"M Merz","year":"2017","unstructured":"Merz, M. et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv. 2, 1\u20139 (2017).","journal-title":"Blood Adv."},{"key":"763_CR38","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"763_CR39","unstructured":"Campbell, T. et al. Uses of anti-BCMA chimeric antigen receptors. Worldwide patent WO2021091978A1 (2021)."},{"key":"763_CR40","unstructured":"Schecter, J. M. & Fan, X. BCMA-targeted CAR-T cell therapy for multiple myeloma. Worldwide patent WO2022116086A1 (2022)."},{"key":"763_CR41","doi-asserted-by":"crossref","unstructured":"Germain, P.-L., Lun, A., Meixide, C. G., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res. 10, 979 (2022).","DOI":"10.12688\/f1000research.73600.2"},{"key":"763_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"763_CR43","doi-asserted-by":"publisher","first-page":"767897","DOI":"10.3389\/fcell.2021.767897","volume":"9","author":"W Koh","year":"2021","unstructured":"Koh, W. & Hoon, S. MapCell: learning a comparative cell type distance metric with Siamese neural nets with applications toward cell-type identification across experimental datasets. Front. Cell Dev. Biol. 9, 767897 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"763_CR44","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"763_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"763_CR46","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1093\/bioinformatics\/btac141","volume":"38","author":"M Andreatta","year":"2022","unstructured":"Andreatta, M., Berenstein, A. J. & Carmona, S. J. scGate: marker-based purification of cell types from heterogeneous single-cell RNA-seq datasets. Bioinformatics 38, 2642\u20132644 (2022).","journal-title":"Bioinformatics"},{"key":"763_CR47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.12688\/f1000research.22969.2","volume":"9","author":"R Fu","year":"2020","unstructured":"Fu, R. et al. clustifyr: an R package for automated single-cell RNA sequencing cluster classification. F1000Res. 9, 223 (2020).","journal-title":"F1000Res."},{"key":"763_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"763_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res. 9, 47 (2020).","journal-title":"F1000Res."},{"key":"763_CR50","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"763_CR51","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"763_CR52","unstructured":"Tickle, T., Tirosh, I., Brown, M. & Haas, B. InferCNV: inferring copy number alterations from tumor single cell RNA-seq data. GitHub https:\/\/github.com\/broadinstitute\/inferCNV\/wiki (2023)."},{"key":"763_CR53","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. iTALK: an R package to characterize and illustrate intercellular communication. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/507871 (2019).","DOI":"10.1101\/507871"},{"key":"763_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30755-0","volume":"13","author":"D Dimitrov","year":"2022","unstructured":"Dimitrov, D. et al. Comparison of methods and resources for cell\u2013cell communication inference from single-cell RNA-seq data. Nat. Commun. 13, 3224 (2022).","journal-title":"Nat. Commun."},{"key":"763_CR55","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao, J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496\u2013502 (2019).","journal-title":"Nature"},{"key":"763_CR56","doi-asserted-by":"publisher","first-page":"658314","DOI":"10.3389\/fimmu.2021.658314","volume":"12","author":"U Blache","year":"2021","unstructured":"Blache, U. et al. Advanced flow cytometry assays for immune monitoring of CAR-T cell applications. Front. Immunol. 12, 658314 (2021).","journal-title":"Front. Immunol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00763-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:44:16Z","timestamp":1727282656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00763-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00763-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2626343\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"24 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F.: consultant and\/or speaker fees from Novartis Pharma, Janssen-Cilag, Vertex Pharmaceuticals (Germany), Kite\/Gilead Sciences, MSGO and Bristol-Myers Squibb. U.K.: consultant and\/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma and Bristol-Myers Squibb. M.M.: advisory boards\/honoraria\/research support from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks and Takeda. K.H.M.: BMS (consultancy and honoraria), AbbVie (honoraria, research funding), Pfizer (honoraria), Otsuka (honoraria), Janssen (honoraria) and Novartis (consultancy). U.P.: Syros (consultancy, honoraria, research funding), MDS Foundation (membership on an entity\u2019s Board of Directors or advisory committees), Silence Therapeutics (consultancy, honoraria, research funding), Celgene (honoraria), Takeda (consultancy, honoraria, research funding), Fibrogen (research funding), Servier (consultancy, honoraria, research funding), Roche (research funding), Merck (research funding), Amgen (consultancy, research funding), Novartis (consultancy, honoraria, research funding), AbbVie (consultancy), Curis (consultancy, research funding), Janssen Biotech (consultancy, research funding), Jazz (consultancy, honoraria, research funding), BeiGene (research funding), Geron (consultancy, research funding) and Bristol-Myers Squibb (consultancy, honoraria, membership on an entity\u2019s Board of Directors or advisory committees, other, travel support, medical writing support, research funding). M.J.: Novartis (honoraria), Amgen (honoraria), Pfizer (honoraria), Blueprint Medicine (honoraria), BMS (honoraria) and Jazz (honoraria). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}